Drug Type CAR-T |
Synonyms BZE 2203, BZE2203 |
Action inhibitors |
Mechanism CTLA4 inhibitors(Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors), MSLN inhibitors(Mesothelin inhibitors), MUC1 inhibitors(Mucin-1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Solid tumor | Preclinical | China | 03 Oct 2024 |





